Japan Drug Makers Eschew Flu Vaccines In Favor Of Treatment
This article was originally published in PharmAsia News
Executive SummaryJapanese drug makers continue turning out flu treatments while their European counterparts concentrate on vaccines to prevent the diseases. Academic institutions are more likely to lead production of vaccines in Japan, with the exception of Denka Seiken, possibly hampering the country's ability to respond to a need for a sudden production increase. Major domestic drug makers in Japan have been reluctant to produce flu vaccines, possibly because they see few profits in doing so, as opposed to higher risks of side effects from the products. (Click here for more - a subscription may be required
You may also be interested in...
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.